AIDS 2010: Track B (Clinical Science) Highlights

Dr. Andrew Kambugu, Uganda (Lead) Jain Vivek, USADr. Gabriel Chamie, USADr. Sabrina Kitaka-Bakera, UgandaDr. Jose Arribas, SpainDr. N. Kumarasamy, IndiaDr. Annie Luetkemeyer, USADr. Ted Ruel UCSF, USA

Track B Stats

AIDS 2010: Track BOA

PD

PE

REJECTED

WITHDRAWN

Result Track B

OA 56

PD 46

PE 544

REJECTED 349

WITHDRAWN 3

TOTAL 998

Structure of Report

• ART: New Drugs and Novel Treatment Strategies• New ART products• Simplification / Switching

• When to Start ART• Co-infections/Co-morbidities

• HIV/TB co-infection• HIV/Hepatitis co-infection• HIV and Malignancies

• Complications of HIV and ART• Monitoring of ART• Paediatrics

Promising Next-generation INI-ING112276

A Nucleoside-Sparing Strategy- The PROGRESS Study

MOAB0103-SPIRAL SLIDE

Treatment Simplification- The SPIRAL Study

Treatment Simplification- The SPARTAN Study

CASCADE-1

When to Start ART- The CASCADE Collaboration

AIDS 2010: THLBB201

CASCADE-2

When to Start ART- The CASCADE Collaboration

AIDS 2010: THLBB201

When to Start ART- The CHER Trial Analysis (Paeds)

When to Start ART- The CAMELIA Trial (TB)

TB/HIV Co-Infection- The Role of IPT in RLS (MOAB0305)

AIDS 2010: MOAB0305

TUAB0104 Slide

HIV/Hepatitis Co-Infection- Risk of Fractures (TUAB0104)

AIDS 2010: TUAB0104

HIV and Malignancies- Higher Burden in HIV (WEAB0101)

AIDS 2010: WEAB0101

?WEAB0304- HIV Comps

HIV and Bone Disease- Association with ART Regimens (WEAB0304)

AIDS 2010: WEAB0304

THAB0102: Monitoring Slide

ART Monitoring: VL vs Non VL sites (THAB0102)

AIDS 2010: THAB0102

THLBB104-PENPACT Slide

Paediatric ART: The PENPACT Study (THLBB104)

AIDS 2010: THLBB104

What Next After CAPRISA 004?

Key Messages

• Newer Drugs may offer simpler, less toxic regimens while maintaining HIV suppression• Nucleoside-sparing regimens (SPARTAN, PROGRESS)

• Start ART earlier• Certain: CD4 less than 350, TB, Peads• Less certain: CD4 less than 500 but >350

• TB and ART: Initiate ART at the earliest opportunity • The CAMELIA

Track B Rapporteur Team

• Dr. Andrew D Kambugu IDI Uganda• Dr. Jain Vivek, UCSF, USA• Dr. Gabriel Chamie, UCSF, USA• Dr. Sabrina Kitaka-Bakera, Makerere, Uganda• Dr. Jose Arribas, Madrid, Spain• Dr. N. Kumarasamy, Chenai, India• Dr. Annie Luetkemeyer, UCSF, USA• Dr. Ted Ruel UCSF, USA